Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Intern Med 2018 Jun 01;178(6):854-856
Date
04/10/2018Pubmed ID
29630687Pubmed Central ID
PMC6145757DOI
10.1001/jamainternmed.2018.0776Scopus ID
2-s2.0-85048229938 (requires institutional sign-in at Scopus site) 38 CitationsAbstract
This study examines the association between oncologists’ receipt of payments from pharmaceutical manufacturers and drug selection in 2 situations where there are multiple treatment options.
Author List
Mitchell AP, Winn AN, Dusetzina SBMESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsConflict of Interest
Drug Industry
Humans
Medicare
Practice Patterns, Physicians'
United States
